

UK Modern Slavery Statement 2025

Introduction

This Statement is made pursuant to section 54(1) of the UK Modern Slavery Act 2015 and is published on behalf of Keenova Therapeutics plc (formerly Mallinckrodt plc) and its group companies.¹ Both Keenova Therapeutics plc and its group companies are referred to as “Keenova” or “Group” for the purpose of this statement. This statement covers the fiscal year ending 31 December 2025.

Keenova is incorporated in Ireland and its principal executive offices are located at College Business & Technology Park, Cruiserath Road, Blanchardstown, Dublin 15, Ireland. We are a global business consisting of multiple wholly-owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies.

As of the close of 2025 fiscal year, no Keenova company falls within the scope of the UK Modern Slavery Act. Keenova’s 2025 UK entities are the following:

- As of the close of full fiscal year ended 31 December 2025: Mallinckrodt ARD Holdings Limited, Mallinckrodt Equinox Limited, Mallinckrodt Medical Holdings (UK) Limited, Mallinckrodt Pharmaceuticals Limited, Mallinckrodt UK Ltd., Mallinckrodt UK Finance LLP, and Sucampo International Holdings Limited;
- From 28 December 2024 to 10 November 2025: Mallinckrodt Chemical Holdings (U.K.) and Mallinckrodt Chemical Limited; and
- From 28 December 2024 to 15 January 2025: Mallinckrodt Enterprises UK Limited, MKG Medical UK Ltd, and MUSHI UK Holdings Limited.

Policies

We have taken several steps to mitigate the risks associated with modern slavery in our business and supply chain. In particular, we support the human rights of our workers and the treatment of all people with dignity and respect through two core policy documents: our Code of Conduct and our Supplier Code of Conduct.

All of our employees are required to be trained on our [Code of Conduct](#) and to certify annually both to their understanding and compliance. Our Code of Conduct reflects our aims for good global citizenship and worldwide social responsibility, including providing clean and safe working environments and conditions free of human rights violations and forbidding forced or child labor across the Group, with no exceptions. The Code of Conduct also prohibits human trafficking or slavery, unsafe or hazardous conditions or environments, or any behavior that does not maintain human dignity and respect. It further provides that Keenova must not engage in activities that fail to protect individual dignity and respect, even if permissible under local law, and must pay a fair wage.

Our [Supplier Code of Conduct](#), which incorporates the Pharmaceutical Supply Chain Initiative (PSCI) guidelines, outlines similar expectations for the ethical behavior of our suppliers and prohibits child and compulsory labor, human trafficking and slavery, unsafe and hazardous working conditions and environments, and other behavior that does not promote human dignity and respect. These standards apply to all suppliers of goods and services to any Group company, regardless of location.

We may take action against anyone found to have violated our Code of Conduct or the Supplier Code of Conduct, which can include termination of employment for employees, removal those providing contract services, or termination contracts and supply agreements.

¹ Mallinckrodt plc completed a merger with Endo, Inc. on 31 July 2025. Following the merger, Mallinckrodt plc then spun off its generics and sterile injectables business as an independent company — Par Health, Inc. — and changed its name to Keenova Therapeutics plc as of 11 November 2025.

Our Code of Conduct and Supplier Code of Conduct are further reinforced by several policies that help to mitigate against the risk of modern slavery, including our Global Safe and Respectful Workplace Policy, Global Contract Review Policy, and Global Source-to-Pay Policy.

Assessment of modern slavery risk

While we believe the risk of modern slavery and human trafficking is relatively low in the highly regulated pharmaceutical industry, as a global company we recognize that our responsibility to ensure that modern slavery and human trafficking are not taking place extends to our business relationships as well.

Our supplier onboarding process includes risk assessment and other due diligence as part of our supplier risk management programme. Moreover, our standard contracts include clauses that subject our suppliers to audits. Keenova conducts audits of its suppliers based on an internal assessment of business and environmental health and safety risk, and measures against recognized industry standards. Among other things, this enables the Group to monitor our suppliers' compliance with our Supplier Code of Conduct.

Due diligence and monitoring

As part of our due diligence screening of all suppliers, we utilize robust third-party due diligence reviews to assist in identifying a range of supplier risks. Any concerns that arise are escalated to our compliance team for further review. In such instances, as part of the process, the Group is immediately restricted from entering any dealings with the identified third party pending conclusion of the compliance team's review.

Keenova also requires compliance with the Supplier Code of Conduct in its contracts with suppliers and other services providers. We utilize an active monitoring tool that identifies any red flags that emerge in respect of an existing supplier. Such cases are reviewed promptly and escalated to the compliance team, as necessary.

Training and communication

All employees are required to complete annual online training on our Code of Conduct, which includes an assessment, and to sign an attestation that they understand and have complied with our Code of Conduct. Employees in relevant functions are also required to read and acknowledge certain other policies relating to our supply chain risk management program.

Keenova encourages reporting of any unethical conduct up through supervisors and the leadership chain of command, or through our Ethics Hotline. The Ethics Hotline is a simple way for employees, suppliers and customers to express concerns regarding any potential unethical situation, including on an anonymous basis. It is managed by an external third party and is operated 24 hours a day. Additional information may be found at <https://secure.ethicspoint.com/domain/media/en/gui/51792/index.html>.

The Group has not received any reports throughout the reporting period in relation to modern slavery risks, including through the Ethics Hotline.

This statement has been approved by our Board of Directors on February 24, 2026.

Signed,



Sigurdur Olafsson
President, Chief Executive Officer and Director